LT3765452T - Dviejų 4-{[(2s)-2-{4-[5-chlor-2-(1h-1,2,3-triazol-1-il)fenil]-5-metoksi-2- oksopiridin-1(2h)-il}butanoil]amino}-2-fluorbenzamido darinių gavimo būdas - Google Patents

Dviejų 4-{[(2s)-2-{4-[5-chlor-2-(1h-1,2,3-triazol-1-il)fenil]-5-metoksi-2- oksopiridin-1(2h)-il}butanoil]amino}-2-fluorbenzamido darinių gavimo būdas

Info

Publication number
LT3765452T
LT3765452T LTEPPCT/EP2019/055815T LTEP2019055815T LT3765452T LT 3765452 T LT3765452 T LT 3765452T LT EP2019055815 T LTEP2019055815 T LT EP2019055815T LT 3765452 T LT3765452 T LT 3765452T
Authority
LT
Lithuania
Prior art keywords
oxopyridin
butanoyl
triazol
chloro
methoxy
Prior art date
Application number
LTEPPCT/EP2019/055815T
Other languages
English (en)
Inventor
Julian Egger
Daniel Götz
Michal SOWA
Original Assignee
Bayer Aktiengesellschaft
Bayer Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft filed Critical Bayer Aktiengesellschaft
Publication of LT3765452T publication Critical patent/LT3765452T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
LTEPPCT/EP2019/055815T 2018-03-15 2019-03-08 Dviejų 4-{[(2s)-2-{4-[5-chlor-2-(1h-1,2,3-triazol-1-il)fenil]-5-metoksi-2- oksopiridin-1(2h)-il}butanoil]amino}-2-fluorbenzamido darinių gavimo būdas LT3765452T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18161983 2018-03-15
PCT/EP2019/055815 WO2019175043A1 (en) 2018-03-15 2019-03-08 Preparative process of two 4-{[(2s)-2-{4-[5-chloro-2-(1h-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2h)-yl}butanoyl]amino}-2-fluorobenzamide derivatives

Publications (1)

Publication Number Publication Date
LT3765452T true LT3765452T (lt) 2022-05-25

Family

ID=61683650

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/EP2019/055815T LT3765452T (lt) 2018-03-15 2019-03-08 Dviejų 4-{[(2s)-2-{4-[5-chlor-2-(1h-1,2,3-triazol-1-il)fenil]-5-metoksi-2- oksopiridin-1(2h)-il}butanoil]amino}-2-fluorbenzamido darinių gavimo būdas

Country Status (29)

Country Link
US (1) US11542245B2 (lt)
EP (2) EP3889147A1 (lt)
JP (1) JP7287978B2 (lt)
KR (1) KR102807521B1 (lt)
CN (1) CN111770917B (lt)
AR (1) AR117400A1 (lt)
AU (1) AU2019236369B2 (lt)
BR (1) BR112020018562A2 (lt)
CA (1) CA3093733A1 (lt)
CL (1) CL2020002371A1 (lt)
DK (1) DK3765452T3 (lt)
ES (1) ES2920449T3 (lt)
HR (1) HRP20220565T1 (lt)
HU (1) HUE058796T2 (lt)
IL (2) IL277240B2 (lt)
JO (1) JOP20200232B1 (lt)
LT (1) LT3765452T (lt)
MX (1) MX2020009580A (lt)
MY (1) MY201167A (lt)
PE (1) PE20211395A1 (lt)
PL (1) PL3765452T3 (lt)
PT (1) PT3765452T (lt)
RS (1) RS63338B1 (lt)
SG (1) SG11202006710RA (lt)
SI (1) SI3765452T1 (lt)
TW (1) TWI823911B (lt)
UA (1) UA126940C2 (lt)
UY (1) UY38147A (lt)
WO (1) WO2019175043A1 (lt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220140558A (ko) * 2020-02-11 2022-10-18 케미노바 에이/에스 (r)-2-아미노부탄산으로부터 s-베플루부타미드를 합성하는 방법
WO2022189280A1 (en) 2021-03-09 2022-09-15 Bayer Aktiengesellschaft Solvates of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoro-methyl)-32 h-6- aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide
MX2023010614A (es) * 2021-03-09 2023-09-19 Bayer Ag Formas cristalinas de (4s)-24-cloro-4-etil-7?-fluoro-35-metoxi-3?, 5-dioxo-14-(trifluoro-metil)-3?h-6-aza-3(4,1)-piridina-1(1)-[1,2, 3]triazola-2(1,2),7(1)-dibencenaheptafano-74-carboxamida.
EP4304561A1 (en) 2021-03-09 2024-01-17 Bayer Aktiengesellschaft Pharmaceutical dosage forms comprising (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5- dioxo-14-(trifluoromethyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)- dibenzenaheptaphane-74-carboxamide
WO2023174399A1 (zh) * 2022-03-18 2023-09-21 苏州晶云药物科技股份有限公司 取代的氧代吡啶类衍生物的晶型及其制备方法
CN116262735B (zh) * 2022-11-18 2025-05-13 成都施贝康生物医药科技有限公司 新型氧代吡啶类化合物及其制备方法和用途
CN116262724B (zh) * 2022-11-18 2025-04-29 成都施贝康生物医药科技有限公司 新型氧代吡啶类化合物及其制备方法和用途
CN116262734B (zh) * 2022-11-18 2025-05-13 成都施贝康生物医药科技有限公司 氧代吡啶类化合物及其制备方法和用途
CN116262740A (zh) * 2022-11-18 2023-06-16 成都施贝康生物医药科技有限公司 新型氧代吡啶类化合物及其制备方法和用途
CN116082303B (zh) * 2022-12-21 2025-02-25 成都施贝康生物医药科技有限公司 新型氧代吡啶类化合物及其中间体和应用
WO2024251276A1 (zh) 2023-06-09 2024-12-12 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体和应用
CN116535392B (zh) * 2023-06-26 2023-09-05 成都施贝康生物医药科技有限公司 一种氧代吡啶类化合物的制备方法及中间体和应用
CN116621742B (zh) * 2023-06-09 2025-05-06 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN116751136B (zh) * 2023-06-21 2025-08-29 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN116621728B (zh) * 2023-06-09 2025-07-29 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN116874387B (zh) * 2023-06-21 2025-08-26 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN116730861A (zh) * 2023-06-21 2023-09-12 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN117164562B (zh) * 2023-09-07 2025-06-13 成都施贝康生物医药科技有限公司 一种氧代哒嗪类化合物及其制备方法和用途
CN117164561A (zh) * 2023-09-07 2023-12-05 成都施贝康生物医药科技有限公司 一种氧代嘧啶类化合物及其制备方法和用途
CN117164565B (zh) * 2023-09-07 2025-05-27 成都施贝康生物医药科技有限公司 一种氧代嘧啶类化合物及其制备方法和用途
CN117164564B (zh) * 2023-09-07 2025-07-08 成都施贝康生物医药科技有限公司 氧代哒嗪类化合物及其制备方法和用途
CN117164563B (zh) * 2023-09-07 2025-06-10 成都施贝康生物医药科技有限公司 氧代嘧啶类化合物及其制备方法和用途
CN117164566B (zh) * 2023-09-07 2025-06-06 成都施贝康生物医药科技有限公司 一种氧代哒嗪类化合物及其制备方法和用途
CN117186073B (zh) * 2023-09-08 2025-06-06 成都施贝康生物医药科技有限公司 氧代嘧啶类化合物及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK9742002A3 (en) * 2000-01-07 2003-02-04 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
TWI633089B (zh) 2013-03-28 2018-08-21 拜耳製藥股份有限公司 經取代的酮基吡啶衍生物
JO3703B1 (ar) * 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
CN107793396B (zh) * 2016-08-31 2021-02-26 江苏恒瑞医药股份有限公司 环氧基取代的氧代吡啶类衍生物、其制备方法及其在医药上的应用
CA3123324A1 (en) * 2018-12-17 2020-06-25 Bayer Aktiengesellschaft Substituted oxopyridine derivatives for the treatment and/or prophylaxis of thrombotic or thromboembolic disorders and/or thrombotic or thromboembolic complications
KR20210106504A (ko) * 2018-12-21 2021-08-30 바이엘 악티엔게젤샤프트 치환된 옥소피리딘 유도체
US20220144848A1 (en) * 2018-12-21 2022-05-12 Bayer Aktiengesellschaft Substituted oxopyridine derivatives

Also Published As

Publication number Publication date
TWI823911B (zh) 2023-12-01
HUE058796T2 (hu) 2022-09-28
JOP20200232A1 (ar) 2020-09-14
UY38147A (es) 2019-10-01
JP7287978B2 (ja) 2023-06-06
CA3093733A1 (en) 2019-09-19
DK3765452T3 (da) 2022-06-27
BR112020018562A2 (pt) 2020-12-29
CN111770917A (zh) 2020-10-13
SG11202006710RA (en) 2020-08-28
PT3765452T (pt) 2022-06-23
AU2019236369B2 (en) 2024-04-18
US20210017152A1 (en) 2021-01-21
WO2019175043A1 (en) 2019-09-19
EP3765452A1 (en) 2021-01-20
US11542245B2 (en) 2023-01-03
JOP20200232B1 (ar) 2023-09-17
PE20211395A1 (es) 2021-07-27
IL277240A (en) 2020-10-29
KR102807521B1 (ko) 2025-05-16
KR20200131241A (ko) 2020-11-23
AR117400A1 (es) 2021-08-04
UA126940C2 (uk) 2023-02-22
IL300463A (en) 2023-04-01
IL277240B2 (en) 2024-01-01
HRP20220565T1 (hr) 2022-06-10
TW202002969A (zh) 2020-01-16
PL3765452T3 (pl) 2022-08-01
RS63338B1 (sr) 2022-07-29
AU2019236369A1 (en) 2020-07-30
ES2920449T3 (es) 2022-08-04
SI3765452T1 (sl) 2022-06-30
IL277240B1 (en) 2023-09-01
RU2020133706A (ru) 2022-04-18
CN111770917B (zh) 2023-09-26
JP2021517573A (ja) 2021-07-26
MY201167A (en) 2024-02-08
MX2020009580A (es) 2020-10-05
EP3889147A1 (en) 2021-10-06
CL2020002371A1 (es) 2021-01-29
EP3765452B1 (en) 2022-04-13

Similar Documents

Publication Publication Date Title
IL277240B1 (en) Process for the preparation of two derivatives of 4-{[(2s)-2-{4-[5-chloro-2-(1h-3,2,1-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridine -1-(2h)-yl}butenoyl]amino}-2-fluorobenzamide
IL281196B (en) Process for the preparation of methyl 6-(4,2-dichlorophenyl)-5-[4-[(s3)-1-(3-fluoropropyl)pyrrolidine-3-yl]oxyphenyl]-9,8-dihydro-h7-benzo[ 7] Anolene-2-carboxylate
LT4192831T (lt) Heterocikliniai glp#1 agonistai
PL4097099T3 (pl) Heterocykliczne agonisty glp-1
DK3724191T3 (da) 5-(2-(2,5-difluorphenyl)pyrrolidin-1-yl)-3-(1h-pyrazol-1-yl)pyrazol[1,5-a]pyrimidinderivater og lignende forbindelser som trk-kinasehæmmere til cancerbehandling
MX2017003791A (es) Procesos para preparar compuestos de (ciclopentil [d]pirimidin-4-il)piperazina.
EP3233824A4 (en) (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3- (methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations
MY199479A (en) Pharmaceutical composition and method for preparing same
IL287078A (en) A process for the preparation of pyrrolidine alpha-carboxamide derivatives
GEP20207127B (en) 2-homopiperazine-1-yl-4h-1,3-benzothiazine-4-one derivatives and process for the preparation of 2-(homo)piperazine 1,3-benzothiazine-4-one hydrochlorides
ZA202204542B (en) Process for the production of 5-(4-((2 s,5 s)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1 h-1,2,4-triazol-3-amine
PH12017500124A1 (en) Azole benzene derivative and crystalline form thereof
EP3233079A4 (en) (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations
TH2001005199A (th) กระบวนการเตรียมของสองอนุพันธ์ 4-{[(2s)-2-{4-[5-คลอโร-2-(1h-1,2,3-ไตรอะซอล-1-อิล) ฟีนิล)-5-เมทอกซี-2-ออกโซไพริดิน-1(2h)-อิล}บิวทาโนอิล]อะมิโน}-2-ฟลูออโรเบนซาไมด์
IL302677B1 (en) History of 1-(2-(4-cyclopropyl-1h-3,2,1-triazol-1-yl)acetyl)-4-hydroxypyrrolidine-2-carboxamide as VHL inhibitors for the treatment of anemia
RU2022129311A (ru) Способ получения двух 4-{ [(2s)-2-{ 4-[5-хлор-2-(1h-1,2,3-триазол-1-ил)фенил]-5-метокси-2-оксопиридин-1(2h)-ил} бутаноил]амино} -2-фторбензамидных производных
HK40108378A (en) Fused heterocyclic derivatives
HK40101052A (en) Heterocyclic glp-1 agonists
IL288732A (en) A process for the preparation of modified pyrazole derivatives
IL307590A (en) 2-((4-((S)-2-(4-CHLORO-2-FLUOROPHENYL)-2-METHYLBENZO[D][1,3]DIOXOL-4-YL)PIPERIDIN-1-YL)METHYL)-1 -(((S)-OXETAN-2-YL)MTHYL)-1H-IMIDAZOLE DERIVATIVES AS ACTIVATORS OF THE GLP1 RECEPTOR FOR THE TREATMENT OF OBESITY
EP3983789B8 (en) Method for determining the concentration of 4-[(4-methyl-1- piperazinyl)methyl]-n-(4-methyl-3-{[4-(3-pyridinyl)-2- pyrimidinyl] - amino} phenyl)benz amide (imatinib) in plasma samples
MX2018008342A (es) Composicion farmaceutica que comprende un derivado azoico de pirazolona biciclo-sustituido o una sal del mismo y metodo de preparacion de los mismos.